Clementia reports Phase II data for rare bone disease candidate

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) reported data from a Phase II trial of palovarotene to treat fibrodysplasia ossificans progressiva (FOP). FOP is a rare, genetic bone disease characterized by heterotopic ossification (HO), or bone formation outside of the normal skeleton in muscles, tendons or soft tissue.

Part B of the open-label, international trial has enrolled 41 evaluable adults and skeletally mature children ages 13 and older to receive a chronic/flare-up dosing regimen of oral palovarotene. Among 33 evaluable patients with 12-month whole body CT scans, palovarotene led to a 28% reduction in whole body volume of new HO compared with 55 untreated control patients. The company powered its Phase III MOVE trial of palovarotene in the indication to detect about a 65% reduction in new HO volume, CEO Clarissa Desjardins said on a conference call to discuss the data...